Abstract:In myeloid malignancies including acute myeloid leukaemia and myelodysplastic syndrome, mutations in spliceosome components drive aberrant RNA splicing and tumourigenesis. Numerous therapeutic strategies have been employed to target this aberrant splicing and achieve splicing‐mutant cell death. Attempted approaches include drugs binding specific spliceosome components, promotion of splicing factor degradation, oligonucleotide therapeutics, and inhibition of splicing factor signalling, methylation, and phosphorylation. Summary In recent years, large‐scale sequencing efforts have identified targetable driver mutations in haematopoietic stem cells. These efforts have led to the development and approval of nine novel agents for relapsed or refractory acute myelogenous leukaemia (R/R AML). However, despite an expansion in targeted therapies, achieving a durable remission in AML and high‐risk myelodysplastic syndrome (HR‐MDS) remains a significant challenge, and there is an urgent need for new effective treatments. Modulation of aberrant RNA splicing has emerged as a novel therapeutic approach in myeloid diseases. Aberrant splicing drives dysregulated gene expression that promotes tumourigenesis through increased proliferation and metastatic potential, immune evasion, decreased apoptosis, and chemotherapy resistance. Mutations in spliceosomal components have been identified in numerous cancer subtypes, with mutations in RNA binding proteins SF3B1, SRSF2, U2AF1, and ZRSR2 occurring frequently in AML and in up to 60% of patients with MDS, as well as in chronic myelomonocytic leukaemia and in 10% of patients with chronic lymphocytic leukaemia. In this review, we explore therapeutic strategies targeting aberrant splicing and the potential of these approaches to drive clinical responses.

Splicing the Difference: Harnessing the complexity of the transcriptome in hematopoiesis

Targeting splicing for hematological malignancies therapy

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Alternative Splicing in Myeloid Malignancies

Alternative pre-mRNA splicing in stem cell function and therapeutic potential: A critical review of current evidence

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

Biological relevance of alternative splicing in hematologic malignancies

Genomics of alternative splicing: evolution, development and pathophysiology

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features

Alternative Splicing Regulation and Cell Lineage Differentiation

RNA Structures in Alternative Splicing and Back‐splicing

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells

Dysregulation and therapeutic targeting of RNA splicing in cancer

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML

Mechanisms of Alternative Splicing Regulation: Insights from Molecular and Genomics Approaches

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Deciphering transcriptional and functional heterogeneity in hematopoiesis with single-cell genomics

Mechanisms of Neuronal Alternative Splicing and Strategies for Therapeutic Interventions

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform